Kristen Ambrose - 24 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
24 Feb 2023
Net transactions value
-$492,211
Form type
4
Filing time
28 Feb 2023, 15:44:44 UTC
Previous filing
03 Feb 2023
Next filing
04 Apr 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $145,138 -502 -5.6% $289.12 8,510 24 Feb 2023 Direct
transaction VRTX Common Stock Sale $282,080 -982 -12% $287.25 7,528 27 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $52,828 -183 -2.4% $288.68 7,345 27 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $12,164 -42 -0.57% $289.63 7,303 27 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1.
F2 Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.25 (range $286.79 to $287.71).
F4 Open market sales reported on this line occurred at a weighted average price of $288.68 (range $288.24 to $289.17).